The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Please scroll further to see how many 1500? That's nowhere near enough. Scroll a bit more 3,000. Sadly, we are not even half-way there. Please keep scrolling Don't give up yet. We are still counting Still counting... A person being ...
Newer vaccines have primarily been introduced in poor countries with support from the Global Alliance for Vaccines and Immunization (GAVI Alliance), but GAVI does not cover vaccination in refugee and crisis-affected populations ...
Those lucky enough to get access to care for drug-resistant tuberculosis go through two years of painful and largely ineffective treatment, taking up to twenty pills a day. Doctors and patients are calling for change. Data: Figures ...